EGFR and non-small cell lung carcinoma: Afatinib has also been combined with cetuximab (Merck), a chimeric monoclonal anti-EGFR antibody and has demonstrated promising clinical activity in EGFR-mutant NSCLC, albeit at the cost of high rates of diarrhea and skin rash (23).